PFA Pension Forsikringsaktieselskab Makes New Investment in Bristol Myers Squibb Company $BMY

Key Points

• PFA Pension Forsikringsaktieselskab opened a new position in Bristol Myers Squibb, acquiring 1,548,577 shares worth about $83.95 million and representing roughly 0.08% of BMY at quarter-end.
• Bristol Myers Squibb reported a Q1 beat (EPS $1.58 vs. $1.42 consensus; revenue $11.49B), management reiterated FY‑2026 guidance and cited growth drugs and cost cuts as drivers, yet the stock traded lower with a consensus price target near $61.31.
• Longer‑term upside is supported by late‑stage pipeline catalysts (milvexian, Cobenfy), but valuation is pressured by the multi‑billion dollar Eliquis patent cliff and a mixed analyst consensus (mostly Hold ratings).

PFA Pension Forsikringsaktieselskab acquired a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,548,577 shares of the biopharmaceutical company's stock, valued at approximately $83,948,000. PFA Pension Forsikringsaktieselskab owned about 0.08% of Bristol Myers Squibb at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of BMY. Man Group plc boosted its position in Bristol Myers Squibb by 280.4% in the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock worth $345,594,000 after purchasing an additional 5,503,391 shares during the last quarter. Two Sigma Investments LP boosted its position in Bristol Myers Squibb by 530.6% in the third quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company's stock worth $245,946,000 after purchasing an additional 4,588,601 shares during the last quarter. Van ECK Associates Corp boosted its position in Bristol Myers Squibb by 67.8% in the third quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company's stock worth $444,682,000 after purchasing an additional 3,982,439 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Bristol Myers Squibb by 31.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 14,833,977 shares of the biopharmaceutical company's stock valued at $669,012,000 after buying an additional 3,522,696 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Bristol Myers Squibb by 56.0% during the 3rd quarter. AQR Capital Management LLC now owns 9,463,981 shares of the biopharmaceutical company's stock valued at $426,352,000 after buying an additional 3,396,041 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.05% of the stock is currently owned by corporate insiders.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY posted a Q1 beat — $1.58 EPS vs. consensus ~$1.42 and $11.49B revenue — driven by growth drugs and Eliquis outperformance, which supports near‑term cash flow. Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales
• Positive Sentiment: Management reiterated FY outlook and emphasized the “growth portfolio” (Breyanzi, Camzyos) and cost‑cutting progress as drivers of durable margin improvement. Bristol-Myers Squibb Signals Confident Path After Q1 Call
• Positive Sentiment: Pipeline catalysts could lift long‑term growth: Phase III readouts for milvexian (potential Eliquis successor) and Cobenfy (schizophrenia) are highlighted as multi‑year drivers. BMS brings the buzz around late-stage readouts amid a so-so Q1
• Neutral Sentiment: Analysts’ consensus price target sits near $61.31, indicating limited upside from current levels absent new positive catalysts. Bristol Myers Squibb Company NYSE: BMY Receives $61.31 Consensus PT from Analysts
• Negative Sentiment: FY 2026 guidance (EPS 6.05–6.35; revenue $46.0–47.5B) left the revenue midpoint slightly below the Street, tempering upside after the quarter and contributing to profit‑taking. Bristol Myers Squibb Reports First Quarter Financial Results for 2026
• Negative Sentiment: Analysts/coverage notes emphasize the scale of the Eliquis patent cliff (multi‑billion dollar risk over coming years), which pressures valuation beyond near‑term beats. Thinning revenues: inside the $14bn Eliquis patent cliff
• Negative Sentiment: Bernstein maintained a Hold rating, signaling that some investors and analysts want clearer evidence that growth and pipeline will offset legacy declines. Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

Bristol Myers Squibb Stock Down 3.9%

Shares of NYSE BMY opened at $58.24 on Friday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The business has a 50-day simple moving average of $59.56 and a two-hundred day simple moving average of $54.48. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The company has a market cap of $118.92 billion, a P/E ratio of 16.88, a P/E/G ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 66.57% and a net margin of 15.01%.The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter last year, the company earned $1.80 EPS. The firm's revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.27 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a $0.63 dividend. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 73.04%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BMY. UBS Group reiterated a "buy" rating and set a $70.00 price target on shares of Bristol Myers Squibb in a research note on Friday, March 6th. HSBC increased their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a "hold" rating in a research note on Tuesday, March 17th. Weiss Ratings reiterated a "hold (c)" rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Guggenheim reiterated a "buy" rating and set a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Finally, Wells Fargo & Company reiterated an "outperform" rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.